Suppr超能文献

在一个全国性的早期肝细胞癌队列中,移植、切除和消融后的生存和预后因素。

Survival and prognostic factors after transplantation, resection and ablation in a national cohort of early hepatocellular carcinoma.

机构信息

Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; Department of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden.

Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

出版信息

HPB (Oxford). 2021 Mar;23(3):394-403. doi: 10.1016/j.hpb.2020.07.010. Epub 2020 Aug 10.

Abstract

BACKGROUND

In patients with early hepatocellular cancer (HCC) and preserved liver function, the choice between transplantation, resection and ablation and which factors to consider is not obvious and guidelines differ. In this national cohort study, we aimed to compare posttreatment survival in patients fulfilling predefined criteria, and to analyse preoperative risk factors that could influence decision.

METHODS

We used data from HCC-patients registered with primary transplantation, resection or ablation 2008-2016 in the SweLiv-registry. In Child A-subgroups, 18-75 years, we compared survival after transplantation or resection, with different tumour criteria; either corresponding to our transplantation criteria (N = 257) or stricter with single tumours ≤50 mm (N = 159). A subgroup with single tumours ≤30 mm, compared all three treatments (N = 193).

RESULTS

We included 1022 HCC-patients; transplantation n = 223, resection n = 438, ablation n = 361. In the transplant criteria subgroup, differences in five-year survival, adjusted for age and gender, were not significant, with 71.2% (CI 62.3-81.3) after transplantation (n = 109) and 63.5% (CI 54.9-73.5) after resection (n = 148). Good liver function (Child 5 vs. 6, Albumin ≥36), increased the risk after transplantation, but decreased the risk after resection and ablation.

CONCLUSION

Even within Child A, detailed liver function assessment is important before treatment decision, and for stratifying survival comparisons.

摘要

背景

在早期肝细胞癌(HCC)且肝功能正常的患者中,肝移植、肝切除术和消融术之间的选择以及需要考虑哪些因素并不明显,指南也存在差异。在本项全国性队列研究中,我们旨在比较符合预定标准的患者治疗后的生存情况,并分析可能影响决策的术前危险因素。

方法

我们使用了 HCC 患者在 2008 年至 2016 年登记于 SweLiv 登记处的肝移植、肝切除术或消融术的数据。在 A 级亚组(18-75 岁)中,我们比较了符合我们的移植标准(n=257)或更严格的肿瘤标准(单个肿瘤直径≤50mm,n=159)的患者在肝移植或肝切除术后的生存情况。在肿瘤直径≤30mm 的亚组中,我们比较了三种治疗方法(n=193)。

结果

我们纳入了 1022 例 HCC 患者;肝移植 223 例,肝切除 438 例,消融术 361 例。在符合移植标准的亚组中,经年龄和性别调整后的五年生存率差异无统计学意义,肝移植组为 71.2%(95%CI 62.3-81.3)(n=109),肝切除组为 63.5%(95%CI 54.9-73.5)(n=148)。良好的肝功能(Child-Pugh 5 级与 6 级,白蛋白≥36g/dl)增加了肝移植后的风险,但降低了肝切除和消融术后的风险。

结论

即使在 A 级患者中,在治疗决策前也需要详细评估肝功能,并对生存情况进行分层比较。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验